Viatris Inc VTRS

NAS: VTRS | ISIN: US92556V1061   30/04/2025
8,420 USD (+0,96%)
(+0,96%)   30/04/2025
Grafiek Viatris Inc Grafiek Viatris Inc
donderdag 8 mei 2025, 13:00
Kwartaalcijfers (1ste kwartaal)

Viatris Inc in het nieuws

29 april 2025 · Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTRS · Persbericht

26 april 2025 · VIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS · Persbericht

25 april 2025 · Viatris to Present at the BofA Securities 2025 Healthcare Conference · Persbericht

25 april 2025 · Class Action Filed Against Viatris Inc. (VTRS) - June 3, 2025 Deadline to Join - Contact Levi & Korsinsky · Persbericht

21 april 2025 · VTRS STOCK NEWS: Stockholders With Large Losses Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the Viatris Inc. Class Action · Persbericht

21 april 2025 · Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

21 april 2025 · Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder · Persbericht

17 april 2025 · ATTENTION NASDAQ: VTRS INVESTORS: Contact Berger Montague About a Viatris Class Action Lawsuit · Persbericht

14 april 2025 · Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer · Persbericht

12 april 2025 · VTRS INVESTOR NOTICE: Viatris, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit · Persbericht

Profiel Viatris Inc

Farmaceutica
Gezondheidstechnologie

CEO: Michael Goettler

Werknemers: 12.348

Mijn selecties